Activity of levofloxacin and ciprofloxacin on biofilms and planktonic cells of Stenotrophomonas maltophilia isolates from patients with device-associated infections

International Journal of Antimicrobial Agents

Volumn 34, Issue 3, 2009, Pages 260-264

  Passerini de Rossi, B ^a   Garcia C ^a   Calenda, M ^a   Vay, C ^b   Franco, M ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

Author keywords

Biofilm susceptibility; Ciprofloxacin; Device associated infections; Levofloxacin; Stenotrophomonas maltophilia

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIOPLANKTON; BACTERIUM ISOLATE; BIOFILM; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE INFECTION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STENOTROPHOMONAS MALTOPHILIA;

ANTI-INFECTIVE AGENTS; ARGENTINA; BIOFILMS; CIPROFLOXACIN; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EQUIPMENT CONTAMINATION; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALS, UNIVERSITY; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; STENOTROPHOMONAS MALTOPHILIA;

EID: 67651021193     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.02.022     Document Type: Article

References (15)

1. Denton M., and Kerr K.G. Microbiological clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 11 (1998) 57-80
2. Sader H.S., and Jones R.N. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int J Antimicrob Agents 25 (2005) 95-109
3. Crossman L.C., Gould V.C., Dow J.M., Vernikos G.S., Okazaki A., Sebaihia M., et al. The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants. Genome Biol 9 (2008) R74
4. Di Bonaventura G., Spedicato I., D'Antonio D., Robuffo I., and Piccolomini R. Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime. Antimicrob Agents Chemother 48 (2004) 151-160
5. Passerini de Rossi B., Calenda M., Vay C., and Franco M. Biofilm formation by Stenotrophomonas maltophilia isolates from device-associated nosocomial infections. Rev Argent Microbiol 39 (2007) 204-212
6. Stewart P.S. Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol 292 (2002) 107-113
7. Barbolla R., Catalano M., Orman B.E., Famiglietti A., Vay C., Smayevsky J., et al. Class 1 integrons increase trimethoprim-sulfamethoxazole MICs against epidemiologically unrelated Stenotrophomonas maltophilia isolates. Antimicrob Agents Chemother 48 (2004) 666-669
8. Nicodemo A.C., and Paez J.I. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis 26 (2007) 229-237
9. Ceri H., Olson M.E., Stremick C., Read R.R., Morck D., and Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37 (1999) 1771-1776
10. Cernohorska L., and Votava M. Determination of minimal regrowth concentration (MRC) in clinical isolates of various biofilm-forming bacteria. Folia Microbiol (Praha) 49 (2004) 75-78
11. Ishida H., Ishida Y., Kurosaka Y., Otani T., Sato K., and Kobayashi H. In vitro and in vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa. Antimicrob Agents Chemother 42 (1998) 1641-1645
12. O'Toole G.A., and Kolter R. Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol Microbiol 30 (1998) 295-304
13. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement. Document M100-S16. Wayne, PA: CLSI; 2006.
14. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Fifteenth informational supplement. Document M100-S15. Wayne, PA: CLSI; 2005.
15. Henrickson K.J., Axtell R.A., Hoover S.M., Kuhn S.M., Pritchett J., Kehl S.C., et al. Prevention of central venous catheter-related infections and thrombotic events in immunocompromised children by the use of vancomycin/ciprofloxacin/heparin flush solution: a randomized, multicenter, double-blind trial. J Clin Oncol 18 (2000) 1269-1278